StreetInsider.com News Articles

Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026

Thu, 15 Oct 2026 07:00:00 -0400

FRIENDSWOOD, Texas, Oct. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2026, after the close of market on Thursday, Nov. 5, 2026.

Company management will host a webcast to discuss

Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026

Thu, 15 Oct 2026 07:00:00 -0400

Company management will host a webcast to discuss

Form 4 CASTLE BIOSCIENCES INC For: Oct 12 Filed by: Juvenal Tobin W

Wed, 14 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261014/27187170.html

Form 144 CASTLE BIOSCIENCES INC Filed by: Juvenal Tobin W

Tue, 13 Oct 2026 08:53:00 -0400

si-local-file:///var/storage/secattach/20261013/27178098.html

Castle Biosciences presents TissueCypher Barrett's data at ACG 2026

Mon, 12 Oct 2026 16:31:31 -0400

Castle Biosciences (Nasdaq: CSTL) announced findings from three studies evaluating its TissueCypher Barrett's Esophagus test at the American College of Gastroenterology 2026 Annual Scientific Meeting in Nashville, Tennessee, running Oct. 9-14.

The studies include two case reports and one multi-center cohort study examining whether the test provides risk information beyond standard biopsy findings for patients with Barrett's esophagus, a precancerous condition linked to esophageal adenocarcinoma.

In the multi-center cohort study, TissueCypher's molecular risk classification showed only slight agreement with the Progression in Barrett's clinicopathologic scoring method, with a Cohen's κ of 0.04. TissueCypher classified 83% of patients as low risk and 17%

ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus

Mon, 12 Oct 2026 16:30:00 -0400

Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings alone

FRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data from three studies evaluating its TissueCypher Barrett's Esophagus (BE) test will be

ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus

Mon, 12 Oct 2026 16:30:00 -0400

Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings alone

Castle Biosciences (CSTL) PT Raised to $39 at Baird

Thu, 08 Oct 2026 07:23:05 -0400

Baird analyst Catherine Schulte raised the price target on Castle Biosciences (NASDAQ: CSTL) to $39.00 (from $38.00) while maintaining a Outperform rating.

Form 4 CASTLE BIOSCIENCES INC For: Oct 05 Filed by: MAETZOLD DEREK J

Wed, 07 Oct 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20261007/27161346.html

Form 144 CASTLE BIOSCIENCES INC Filed by: MAETZOLD DEREK J

Mon, 05 Oct 2026 18:24:00 -0400

si-local-file:///var/storage/secattach/20261005/27150298.html

Form 4 CASTLE BIOSCIENCES INC For: Oct 01 Filed by: Oelschlager Kristen M

Mon, 05 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261005/27148806.html

Form 144 CASTLE BIOSCIENCES INC Filed by: Oelschlager Kristen M

Thu, 01 Oct 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20261001/27136330.html

Form 4 CASTLE BIOSCIENCES INC For: Sep 29 Filed by: Juvenal Tobin W

Thu, 01 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261001/27136281.html

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

Wed, 30 Sep 2026 16:30:00 -0400

Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-free survival (RFS) of 99.6%

Separate ePoster shows DecisionDx-Melanoma identifies early-stage, transected melanomas with recurrence risk similar to that seen in stage IIB disease, supporting closer surveillance when staging is uncertain

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

Wed, 30 Sep 2026 16:30:00 -0400

New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus

Mon, 28 Sep 2026 07:00:00 -0400

FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study showing that its TissueCypher^® Barrett's Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett's esophagus (NDBE). In the study, clinicians changed their management recommendations 90% of the time after receiving TissueCypher results, including escalating management for all patients with intermediate- or high-risk results

New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus

Mon, 28 Sep 2026 07:00:00 -0400

New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™

Thu, 24 Sep 2026 16:30:00 -0400

Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacy

Among patients surveyed in the study, 94% of those open to a new systemic therapy expressed interest in molecular testing to help identify a more effective treatment

New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™

Thu, 24 Sep 2026 16:30:00 -0400

Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacy

Among patients surveyed in the study, 94% of those open to a new systemic therapy expressed interest in molecular testing to help identify a more effective treatment

Form 4 CASTLE BIOSCIENCES INC For: Sep 21 Filed by: MAETZOLD DEREK J

Wed, 23 Sep 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260923/27097002.html

Castle Biosciences opens 55,000-sq-ft lab in Scottsdale, Arizona

Tue, 22 Sep 2026 07:03:53 -0400

Castle Biosciences (Nasdaq: CSTL) has opened a new 55,000-square-foot laboratory and office facility in Scottsdale, Arizona, according to a company press release. A grand opening event is scheduled for October 6, 2026, at the site located at 8667 E. Hartford Drive.

The facility sits within the 260-acre Perimeter Center business park and expands the company's operational presence in the Phoenix metropolitan area. Infrastructure at the new location includes upgraded HVAC, IT and security systems, as well as backup power redundancy systems.

Kristen Oelschlager, chief operating officer of Castle Biosciences, said the investment provides teams with "additional space, infrastructure and capacity to support

Castle Biosciences to Open New Laboratory Facility in Scottsdale

Tue, 22 Sep 2026 07:00:00 -0400

New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growth

FRIENDSWOOD, Texas, Sept. 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the opening of its new laboratory and office facility in Scottsdale, Arizona.

Castle Biosciences to Open New Laboratory Facility in Scottsdale

Tue, 22 Sep 2026 07:00:00 -0400

New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growth

Form 4 CASTLE BIOSCIENCES INC For: Sep 14 Filed by: Juvenal Tobin W

Wed, 16 Sep 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260916/27070529.html

Form 4 CASTLE BIOSCIENCES INC For: Sep 11 Filed by: MAETZOLD DEREK J

Tue, 15 Sep 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260915/27064923.html